USE OF FGFR1 EXTRA CELLULAR DOMAIN PROTEINS TO TREAT CANCERS CHARACTERIZED BY LIGAND-DEPENDENT ACTIVATING MUTATIONS IN FGFR2

• 收藏
• 分享

专利权人:

FIVE PRIME THERAPEUTICS; INC.

发明人:

THOMAS HARDING,MICHAEL W. KAVANAUGH

申请号：

PT10830834

公开号：

PT2498799T

申请日:

2010.11.12

申请国别(地区):

PT

年份:

2016

代理人:

摘要：

The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/